Trial · NCT03131999

LAM Pilot Study With Imatinib Mesylate

NCT03131999, Phase 1, Phase 2, Completed, Medical University of South Carolina; results first posted 2020-03-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. LAM Pilot Study With Imatinib Mesylate. Trials, record NCT03131999. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03131999

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: LAM Pilot Study With Imatinib Mesylate
NCT number: NCT03131999
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 18 participants, actual
Lead sponsor: Medical University of South Carolina
Conditions: Lymphangioleiomyomatosis
Interventions: Imatinib Mesylate 400Mg Capsule, Placebo - Capsule
First posted: 2017-04-27
Last updated: 2020-06-16
Results first posted: 2020-03-26

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Serum VEGF-D	Before and 1 month after initiation of monotherapy imatinib mesylate or placebo	Change in the square root of the intrasubject plasma VEGF-D
Secondary	Adverse Events	3 months	Adverse event and Serious Adverse Event numbers using the CTCAE Version 4.03 definitions
Other	Lung Function	2 months	FEV1 % predicted change
Other	SGRQ	2 months	Saint Georges Respiratory Questionnaire change

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Serum VEGF-D	Before and 1 month after initiation of monotherapy imatinib mesylate or placebo	Log transformed VEGF-D change pg/dL	MEAN
SECONDARY	Adverse Events	3 months	number of events	NUMBER
OTHER_PRE_SPECIFIED	Lung Function	2 months
OTHER_PRE_SPECIFIED	SGRQ	2 months

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Serum VEGF-D	Imatinib Mesylate 400mg Capsule		0.05	Standard Deviation 0.10	Log transformed VEGF-D change pg/dL
Serum VEGF-D	Placebo Capsule		0.07	Standard Deviation 0.13	Log transformed VEGF-D change pg/dL
Adverse Events	Imatinib Mesylate 400mg Capsule	Adverse Events	10		number of events
Adverse Events	Placebo Capsule	Adverse Events	12		number of events
Adverse Events	Imatinib Mesylate 400mg Capsule	Serious Adverse Events	0		number of events
Adverse Events	Placebo Capsule	Serious Adverse Events	0		number of events

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Imatinib Mesylate 400mg Capsule	8
Overall Study	STARTED	Placebo Capsule	8
Overall Study	COMPLETED	Imatinib Mesylate 400mg Capsule	8
Overall Study	COMPLETED	Placebo Capsule	7
Overall Study	NOT COMPLETED	Imatinib Mesylate 400mg Capsule	0
Overall Study	NOT COMPLETED	Placebo Capsule	1

Source ClinicalTrials.gov

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nausea and/or vomitting	Gastrointestinal disorders	Imatinib Mesylate 400mg Capsule	4	8	4
other	Nausea and/or vomitting	Gastrointestinal disorders	Placebo Capsule	4	7	4
other	Fatigue	General disorders	Imatinib Mesylate 400mg Capsule	3	8	3
other	Fatigue	General disorders	Placebo Capsule	0	7	0
other	Insomnia	General disorders	Imatinib Mesylate 400mg Capsule	0	8
other	Insomnia	General disorders	Placebo Capsule	2	7	2
other	Headache	Nervous system disorders	Imatinib Mesylate 400mg Capsule	0	8	0
other	Headache	Nervous system disorders	Placebo Capsule	3	7	3
other	Elevated Trough Sirolimus	Respiratory, thoracic and mediastinal disorders	Imatinib Mesylate 400mg Capsule	2	8	2
other	Elevated Trough Sirolimus	Respiratory, thoracic and mediastinal disorders	Placebo Capsule	1	7	1

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Imatinib Mesylate 400mg Capsule	0	8
Total, all-cause mortality	Placebo Capsule	0	7
Total, other adverse events	Imatinib Mesylate 400mg Capsule	8	8
Total, other adverse events	Placebo Capsule	5	7
Total, serious adverse events	Imatinib Mesylate 400mg Capsule	0	8
Total, serious adverse events	Placebo Capsule	0	7

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Imatinib Mesylate 400mg Capsule vs Placebo Capsule: deaths from any cause	Trial comparisons
Imatinib Mesylate 400mg Capsule vs Placebo Capsule: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03131999

GET https://conductscience.org/api/trials/v1/NCT03131999/registered

API reference For AI assistants